Viridian Shares New 52-Week Phase III Trial Data for Active TED
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…
LKC’s RETeval™ Device Leads the Revolution in Electroretinography
Advances in electroretinography (ERG) means it’s time for this tech to have its day in the sun – and in…
latest posts
